TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04481815
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 25mg orally d1-10 every 3 weeks for 1 cycle, 6 cycles will be prescribed for induction therapy. 25mg orally d1-14,d29-42 every 8 weeks for 1 cycle, 4 cycles will be prescribed for maintenance therapy.
Study: NCT03068442
Drug: Imaging with flutemetamol F 18 PET/CT
DrugBank: Flutemetamol (18F) (DB09151)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All subjects will undergo diagnostic imaging as the intervention. This imaging will be with flutemetamol F 18 PET/CT
Study: NCT03570931
Drug: RT001
Normalized name: Risankizumab
DrugBank: Risankizumab (DB14762)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: RT001 is encapsulated di-deutero synthetic homologue of linoleic acid ethyl ester. Each capsule contains 960 mg of RT001.
Study: NCT00096707
Drug: 2-deoxy-D-glucose (2DG)
DrugBank: 2-deoxyglucose (DB08831)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03115307
Drug: Triptorelin
Normalized name: triptorelin
DrugBank: Triptorelin (DB06825)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triptorelin 0,1mg/ml subcutaneously once in a luteal phase in insemination cycles.
Study: NCT01246440
Drug: Catumaxomab
Normalized name: catumaxomab
DrugBank: Catumaxomab (DB06607)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Catumaxomab: 4 intraperitoneal infusions of catumaxomab over 11 days administered in a period of 3 hours through an intraperitoneal catheter with the following dosage: 1) 10 µg on Day 0. 2) 20 µg on Day 3. 3) 50 µg on Day 7. 4) 200 µg on Day 10.
Study: NCT00838630
Drug: Cilostazol 100 mg tablets
Normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 x 100 mg
Study: NCT03539055
Drug: Dabigatran Etexilate Oral Capsule
Normalized name: dabigatran etexilate Oral Capsule
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral use of Dabigatran etexilate for 90 days BID per product labeling for dosage to reduce incidence of device related thrombus after implantation of a Watchman LAA device.
Study: NCT01392911
Drug: Rifampicin
Normalized name: Rifampicin
DrugBank: Rifampin (DB01045)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High dose rifampicin
Study: NCT01227044
Drug: Naltrexone
Normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NTX arm will receive monthly extended release NTX doses at 380mg (4 mL), administered as an intramuscular gluteal injection at 4-week intervals.
Study: NCT01342835
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The induction dose of propofol is 3-5 mg/kg-1 (mean induction dose: 4 mg/kg-1) follow by propofol infusion (12 mg/kg/h-1 for the first 10 min of general anesthesia, 9 mg/kg/h-1 for another 10 min, and 6 mg/kg/h-1 thereafter; mean maintenance dose: 9 mg/kg/h-1) and a 50:50 mixture of N2O and O2.
Study: NCT02184078
Drug: Nevirapine
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02184078
Drug: Rifabutin
Normalized name: Rifabutin
DrugBank: Rifabutin (DB00615)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01732809
Drug: AbobotulinumtoxinA (ABO)
Normalized name: abobotulinumtoxinA
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Isovolumetric (0.02 mL) doses of 2 units of abobotulinumtoxinA injected on one side of the forehead.
Study: NCT01732809
Drug: OnabotulinumtoxinA (ONA)
Normalized name: Onabotulinumtoxina
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Isovolumetric (0.02 mL) doses of 2 units of onabotulinumtoxinA injected on the other side of the forehead.
Study: NCT02267694
Drug: Freeze-dried black raspberry powder
Normalized name: BLACKBERRY MESOCARP FREEZE DRIED
DrugBank: Raspberry (DB10636)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01897454
Drug: Gemcitabine Hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01897454
Drug: Irinotecan Hydrochloride
Normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00884273
Drug: Degarelix
Normalized name: Degarelix
DrugBank: Degarelix (DB06699)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The second and third doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections on Days 28 and 56, respectively.
Study: NCT00884273
Drug: Goserelin
Normalized name: Goserelin
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Goserelin implants (3.6 mg) were inserted s.c. into the abdominal wall every 28 days. The first dose was administered on Day 0. The second and third doses of goserelin were administered on Days 28 and 56, respectively.
Study: NCT04561063
Drug: Nitazoxanide
Normalized name: Nitazoxanide
DrugBank: Nitazoxanide (DB00507)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitozoxanide 1 tablet (500 mg) taken 12-hourly with food for the first week, followed by 2 tablets (1000 mg) taken 12-hourly with food thereafter. (Participants that fail to tolerated the 1000 mg 12-hourly dose may revert back to the lower dose.)
Study: NCT01897454
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00884273
Drug: Bicalutamide
Normalized name: Bicalutamide
DrugBank: Bicalutamide (DB01128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: On Day 0, participants began once-daily per-oral (p.o.) treatment with bicalutamide (50 mg) as anti-androgen flare protection; this treatment continued for 28 days after the first dose of goserelin.
Study: NCT03179332
Drug: BioChaperone® insulin lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single subcutaneous administration of a bolus of 0.15 U/kg body with a pump
Study: NCT00094978
Drug: Flavopiridol (alvocidib)
Normalized name: Flavopiridol
DrugBank: Alvocidib (DB03496)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04034485
Drug: lerodalcibep
Normalized name: Lerodalcibep
DrugBank: Lerodalcibep (DB19071)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCSK9 inhibitor
Study: NCT04034485
Drug: evolocumab
Normalized name: Evolocumab
DrugBank: Evolocumab (DB09303)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: PCSK9 inhibitor
Study: NCT04561063
Drug: Sofosbuvir/Daclatasvir
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sofosbuvir/daclatasvir 400mg/60 mg sofosbuvir/daclatasvir fixed dose combination 1 tablet daily
Study: NCT00044135
Drug: clevudine (drug)
Normalized name: zinc pyrithione
DrugBank: Clevudine (DB06683)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00113386
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00113386
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01673867
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03944356
Drug: Dabrafenib and Trametinib
Normalized name: Dabrafenib
DrugBank: Trametinib (DB08911)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dabrafenib and trametinib treatment under routine conditions according to the applying SmPC.
Study: NCT02598661
Drug: Imetelstat Sodium
Normalized name: imetelstat sodium
DrugBank: Imetelstat (DB14909)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imetelstat sodium IV infusion.
Study: NCT01972490
Drug: avastin
Normalized name: Avastin
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Drug: avastin On day 1 of a 14 day treatment cycle, patients received a 2-hour infusion of avastin (5mg/kg) followed by chemotherapy of mFOLFOX6 until progressive disease or unacceptable toxicity.
Study: NCT02008682
Drug: liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered subcutaneously (s.c., under the skin) once daily as add-on to the subject's stable pre-trial metformin dose.
Study: NCT02008682
Drug: sitagliptin
Normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered orally once daily as add-on to the subject's stable pre-trial metformin dose.
Study: NCT01839279
Drug: Tizanidine
Normalized name: Tizanidine
DrugBank: Tizanidine (DB00697)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01839279
Drug: Moxifloxacin
Normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04430985
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Day 1 in cycle 1-4: 100 mg/m2 intrahepatic administration Day 1 in cycle 5-8: oxaliplatin 85 mg/m2 i.v.
Study: NCT04430985
Drug: 5-Fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Day 1 each cycle: 400 mg/m2 i.v. bolus, 2400 mg/m2 i.v.over 46 hrs
Study: NCT04430985
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Day 3 in cycle 3 to 8: 3 mg/kg i.v.
Study: NCT03142165
Drug: BMS-986263
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 3 weekly doses of 90 mg infused intravenous administration
Study: NCT03142165
Drug: Diphenhydramine
Normalized name: Diphenhydramine
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg intravenous administration
Study: NCT03142165
Drug: Famotidine
Normalized name: Famotidine
DrugBank: Famotidine (DB00927)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg intravenous administration
Study: NCT00042978
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00042978
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00682500
Drug: Calfactant
Normalized name: Calfactant
DrugBank: Calfactant (DB06415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intratracheal Instillation of 0.5 mL/cm of height of 60 mg/mL suspension in two aliquots at study entry. Repeat dosing 12 hours later if criteria are met.
Study: NCT00682500
Drug: Room Air (placebo)
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of 0.5 ml/cm height of air at study entry into the trachea. Repeat dosing at 12 hours if criteria are met
Study: NCT02013154
Drug: DKN-01 150 mg
Normalized name: Dkk1-neutralizing monoclonal antibody dkn-01
DrugBank: Sirexatamab (DB17515)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by IV infusion
Study: NCT02013154
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered by IV infusion
Study: NCT02013154
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered by IV infusion
Study: NCT02013154
Drug: DKN-01 300 mg
Normalized name: Dkk1-neutralizing monoclonal antibody dkn-01
DrugBank: Sirexatamab (DB17515)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by IV infusion
Study: NCT03318159
Drug: Posaconazole
Normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dosing of posaconazole Posaconazole tablet 300 mg twice daily on day 1; Maintenance dose: 300 mg once daily on day 2 and thereafter. Treatment period: 4 weeks~\*if posaconazole tablet intolerance: posaconazole suspension 200mg tid
Study: NCT01285544
Drug: Atorvastatin (Lipinon)
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: treatment of dyslipidemia administration : PO, qod
Study: NCT01285544
Drug: Atorvastatin (Lipitor)
Normalized name: atorvastatin Oral Tablet [Lipitor]
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: treatment of dyslipidemia administration : PO, qod
Study: NCT00034632
Drug: Posaconazole oral suspension
Normalized name: Posaconazole Oral Suspension
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01827605
Drug: BEAM
Normalized name: Beam
DrugBank: Tricyclazole (DB02891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BEAM REGIMEN day -6 Carmustine\* 300 mg/ m2 i.v. in 250ml dextrose 5% solution~from day -5 to day -2 Cytarabine 200 mg/m2 i.v. every 12 hours in 250 ml dextrose 5% solution, 250 ml/hr Etoposide 100 mg/m2 i.v. every 12 hours in 250 ml dextrose 5% solution, 250 ml/hr day -1 Melphalan 140 mg/m2 i.v. in 100ml saline solution in 200 ml/hr~day 0~UReinfusion of autologous stem cells following this rules:~1. Patient collecting ≥6x106 CD34+ cells/kg use \>4x106 CD34+ cells/kg for ASCT and keep \>2x106 CD34+ cells/kg for back up;~2. Patient collecting 4-6x106 CD34+ cells/kg use \>2x106 CD34+ cells/kg for ASCT and keep \>2x106 CD34+ cells/kg for back up;~3. Patient collecting 2-4x106 CD34+ cells/kg use all CD34+ cells for ASCT and keep no back up.~day 2 Filgrastim or Lenograstim 5μg/Kg s.c. until ANC \> 1500/mmc
Study: NCT03961503
Drug: Daptomycin (DAP) treatment
Normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group DAP : Daptomycin was administered at a dose of 8 mg/kg in thirty-minutes intravenous infusion every 24 hours in patients without severe impairment of kidney function or every 48 hours in case of GFR below 30 ml/min/m2. The creatine-kinase (CK) level was measured before the initiation of DAP and at least once a week to assess the occurrence of muscular toxicity defined by an increase of CK up to 3-fold the upper superior limit without any evidence of member ischaemia.
Study: NCT00573417
Drug: modafinil
Normalized name: Modafinil
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: modafinil 100mg tablets. dose excalation up to 300mg
Study: NCT03961503
Drug: Vancomycin (VAN) treatment
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group VAN : Vancomycin intravenous treatment was initiated by a loading dose of 30 mg/kg in 1 hour and followed by a continuous maintenance infusion dosing between 15 and 30 mg/kg/d. The VAN dose was adapted to achieve a target serum vancomycin steady-state concentration of 20-30 mg/L assessed by a daily pharmacologic monitoring (therapeutic drug monitoring).
Study: NCT02568800
Drug: Prolonged Cefepime Infusion
DrugBank: Cefepime (DB01413)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefepime infusion should last at least 4 hours with the aide of an infusion bomb
Study: NCT02568800
Drug: Usual Cefepime Infusion
DrugBank: Cefepime (DB01413)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefepime infusion occurs directly without the aide of an infusion bomb, lasting roughly thirty minutes
Study: NCT00025272
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00025272
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00025272
Drug: topotecan hydrochloride
Normalized name: Topotecan Hydrochloride
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03679598
Drug: Alvelestat (MPH966)
Normalized name: Alvelestat
DrugBank: Alvelestat (DB11863)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alvelestat was developed as treatment for lung diseases like Chronic Obstructive Pulmonary Disease. Alevelestat works by blocking certain proteins in the body that are responsible for inflammation and damage to the lungs that can lead to COPD symptoms.
Study: NCT03723824
Drug: grazoprevir 100 mg/ elbasvir 50 mg, Zepatier®
DrugBank: Elbasvir (DB11574)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: grazoprevir 100 mg/ elbasvir 50 mg (Zepatier®, MSD) once daily for 12 weeks
Study: NCT04788121
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The treatment group will receive Injection TXA 1gm intravenous (IV) over 15 minutes infusion dissolved in 100 ml normal saline (NS- 0.9% NaCl), followed by injection TXA 2 g IV over 12 hours infusion dissolved in a 500 ml NS
Study: NCT00345176
Drug: Lutein/zeaxanthin and DHA/EPA
DrugBank: Lutein (DB00137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg lutein and 2 mg zeaxanthin (1 tablet) 350 mg DHA and 650 mg EPA (2 soft-gel capsules)
Study: NCT03375047
Drug: MRT5005
Normalized name: MRT5005
DrugBank: MRT5005 (DB18260)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulization of MRT5005
Study: NCT02195583
Drug: Sodium fluoride (1426 ppm)
Normalized name: Sodium Fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-zinc, 1426ppm fluoride as sodium fluoride in a silica gel base
Study: NCT02195583
Drug: Sodium fluoride (1150 ppm)
Normalized name: Sodium Fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-zinc, 1150ppm fluoride as sodium fluoride in a silica gel base
Study: NCT02195583
Drug: Sodium fluoride (250 ppm)
Normalized name: Sodium Fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-zinc, 250ppm fluoride as sodium fluoride in a silica gel base
Study: NCT00004420
Drug: gamma-Linolenic acid
Normalized name: gamma-linolenic acid
DrugBank: Gamolenic acid (DB13854)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00685503
Drug: Ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02788240
Drug: Terlipressin 1- 4mg,if indicated
DrugBank: Terlipressin (DB02638)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02788240
Drug: Meropenem or Imepenem, if indicated
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03045562
Drug: Salvianolate injection
Normalized name: Salvianolic acid A
DrugBank: Salvianolic acid A (DB15246)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be assigned to receive Salvianolate injection dissolved in 100ml of normal saline in catherter room setting,and following similar medicine once daily for 7 days.
Study: NCT00623428
Drug: peginterferon alfa-2a
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00623428
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00927069
Drug: Adalimumab every other week
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab 40mg injection every other week for 24 weeks
Study: NCT00927069
Drug: Adalimumab Every Week
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab 40mg injection every week for the last 12 weeks of study.
Study: NCT00397787
Drug: sunitinib malate
Normalized name: Sunitinib Malate
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT02450682
Drug: Apixaban
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Anticoagulant agent for Atrial Fibrillation and undergo CIED generator change
Study: NCT02450682
Drug: Warfarin
Normalized name: Warfarin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anticoagulant agent for Atrial Fibrillation and undergo CIED generator change
Study: NCT01244620
Drug: sitaxentan
Normalized name: Sitaxentan
DrugBank: Sitaxentan (DB06268)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: sitaxsentan 100 mg QD for 6 days
Study: NCT01244620
Drug: tadalafil
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tadalafil 40 mg QD for 6 days
Study: NCT01244620
Drug: sitaxsentan
Normalized name: Sitaxsentan
DrugBank: Sitaxentan (DB06268)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: sitaxsentan 100 mg QD for 6 days
Study: NCT02195583
Drug: Fluoride (0 ppm)
Normalized name: Hydrogen fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-zinc, 0ppm fluoride in a silica gel base
Study: NCT02620696
Drug: netazepide
Normalized name: Netazepide
DrugBank: Netazepide (DB12355)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02573363
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given per standard of care
Study: NCT02573363
Drug: Mitoxantrone Hydrochloride
Normalized name: Mitoxantrone Hydrochloride
DrugBank: Mitoxantrone (DB01204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given per standard of care
Study: NCT02573363
Drug: Selinexor
Normalized name: Selinexor
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT01244620
Drug: sitaxsentan
Normalized name: Sitaxsentan
DrugBank: Sitaxentan (DB06268)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: sitaxentan 100 mg QD for 6 days
Study: NCT01244620
Drug: sildenafil
Normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sildenafil 20 mg TID for 6 days
Study: NCT03872128
Drug: Pregnenolone300
DrugBank: Pregnenolone (DB02789)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300mg
Study: NCT01367535
Drug: SC Methylnaltrexone (MNTX)
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01367535
Drug: IV Methylnaltrexone (MNTX)
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01367535
Drug: Oral Paroxetine
DrugBank: Paroxetine (DB00715)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04341441
Drug: Hydroxychloroquine - Daily Dosing
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The daily hydroxychloroquine treatment arm will receive a 200 mg oral dose daily following day 1 dose of 400 mg orally once. This dose represents approximately half the standard weight-based dosing recommended for management of autoimmune diseases and therefore less likely to produce side effects than standard of care.~All treatment groups will receive placebo pills to have the patients take 2 pills a day.
Study: NCT04341441
Drug: Hydroxychloroquine - Weekly Dosing
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The once weekly randomized treatment arm will receive the proposed dose of hydroxychloroquine for prophylaxis of malaria is 6.5 mg/kg per dose (maximum of 400 mg per dose) administered orally weekly on the same day of each week. This is based on the recommended dose for prophylaxis of malaria~All treatment groups will receive placebo pills to have the patients take 2 pills a day.